ϩ CTL play a pivotal role in a variety of human illnesses. They are needed to control the acute and chronic stages of most viral infections, including HIV, hepatitis B virus, and the herpes viruses (e.g., HSV, CMV, and EBV) (1-6). CTL are also thought to play a role in cancer surveillance, and CTL clones raised against tumor Ags have been used successfully in adoptive immunotherapy regimens (7-10). However, CTL can cause life-threatening illnesses such as transplant rejection, graft-vshost disease, and autoimmunity (11-13). Thus, CTL are linked to both preventing and promoting pathogenesis, and the ability to specifically modulate CTL function is an attractive therapy concept.
C D8
ϩ CTL play a pivotal role in a variety of human illnesses. They are needed to control the acute and chronic stages of most viral infections, including HIV, hepatitis B virus, and the herpes viruses (e.g., HSV, CMV, and EBV) (1) (2) (3) (4) (5) (6) . CTL are also thought to play a role in cancer surveillance, and CTL clones raised against tumor Ags have been used successfully in adoptive immunotherapy regimens (7) (8) (9) (10) . However, CTL can cause life-threatening illnesses such as transplant rejection, graft-vshost disease, and autoimmunity (11) (12) (13) . Thus, CTL are linked to both preventing and promoting pathogenesis, and the ability to specifically modulate CTL function is an attractive therapy concept.
CTL are a critical component of many successful immune responses, but they have the potential to injure the host. Therefore, their activity is closely regulated by multiple receptor-ligand interactions. Before they can function as effectors, CTL must be activated by APCs and triggered by target cells. Once activated, the immune system has mechanisms to control the CTL response and prevent the destruction of healthy host cells. Activated CTL can be depleted through Fas-mediated apoptosis, a process called activation-induced cell death. Alternatively, activated CTL can become anergic or differentiate into a functionally impaired, nonresponsive, or memory-like state (14 -16) .
Because CTL are involved in controlling the acute, lytic phase and persistent, latent phase of HSV infection, HSV has evolved numerous mechanisms to evade CTL as part of its survival strategy. HSV-infected cells can avoid CTL detection by interfering with TAP-mediated peptide loading onto MHC (17) (18) (19) . Furthermore, several HSV genes have been shown to inhibit CTL-induced apoptosis of HSV-infected target cells (20 -24) . An alternative mechanism has been described, wherein HSV-infected cells were capable of inhibiting the lytic function of various immune effector cells (25) (26) (27) . In these models, when effector cells were incubated with HSV-infected fibroblasts, they lost the ability to lyse subsequently added target cells. However, the significance of these initial findings was not appreciated, as subsequent efforts focused on the cell-to-cell spread of HSV to effector cells (28, 29) . In addition, it was reported that HSV-infected CTL expressed increased levels of Fas ligand and thus could be silenced through fratricide-induced apoptosis (30) .
In this study, we demonstrate that HSV-infected fibroblasts transmit a functionally inhibiting signal to CTL without infecting CTL or inducing apoptosis in CTL. We refer to this process as inactivation. The inactivating signal markedly decreases the cytotoxic and cytokine effector functions of CTL, and the inactivated phenotype is sustainable after CTL are removed from HSV-infected cells and treated with IL-2. Although inactivated CTL cannot be stimulated through the TCR, they are capable of secreting IFN-␥ when treated with a phorbol ester plus ionomycin. Finally, we have shown that HSV-infected fibroblasts require the expression of a viral protein kinase, U S 3, to transmit the inactivating signal to CTL. Our HSV-mediated inactivation model may elucidate a mechanism that would allow specific manipulation of CTL function.
described (31, 32) . SKH13, KSN, and the EBV-immortalized lymphoblastoid B cell lines (LCL), CEPH-8240 (mHA-8 positive), SDK (mHA-8 negative), KSN-(peptide positive), and GAO (peptide negative) were kindly provided by E. Warren at the Fred Hutchinson Cancer Research Center. LCLs were grown in RPMI 1640 supplemented with 4 mM HEPES, 3 mM L-glutamine, 10% FCS, 50 U/ml penicillin, and 50 g/ml streptomycin. Fibroblasts were obtained from human foreskin samples and maintained in DMEM, 10% FCS, 50 U/ml penicillin, and 50 g/ml streptomycin. Human fibroblasts were used in assays from passage 5 to 12. Vero cells were obtained from the American Type Culture Collection (Manassas, VA) and grown in the same medium as fibroblasts. Cells were screened regularly for mycoplasma by the Biologics Production Facility at the Fred Hutchinson Cancer Research Center.
The wild-type viruses HSV-1 strain F (provided by J. Blaho (Mt. Sinai School of Medicine, New York, NY), originally obtained from B. Roizman (University of Chicago, Chicago, IL) (33)) and HSV-2 strain HG52 were used in the experiments, as indicated. The mutant viruses were deletionrescue pairs derived from HSV-1 F. The U L 54 (ICP27) deletion and rescue viruses, vBS⌬27 and vBS⌬27R, were provided by J. Blaho and originally obtained from P. Schaffer (Harvard Medical School, Boston, MA) (34) . The U S 12 deletion and rescue viruses, ICP47⌬ and ICP47⌬R, were provided by D. Johnson (Oregon Health and Science University, Portland, OR) (29) . The U S 3 deletion and rescue viruses, R7041 and R7306, were provided by B. Roizman (35) . The U S 5 deletion and rescue viruses, RAS116 and RAS137, were provided by A. Sears (Tampa Bay Research Institute, St. Petersburg, FL) (22) . Because the ␣4 (ICP4) rescue virus was not available, the ␣4 deletion virus d120 was compared with HSV-1 parent strain KOS 1.1. These viruses were provided by J. Smiley (University of Alberta, Edmonton, Alberta, Canada) and originally obtained from N. DeLuca (University of Pittsburgh, Pittsburgh, PA) (36) . All viruses were grown on Vero cells and titered using standard plaque assays.
Cell-mediated cytotoxicity assays
Fibroblasts were grown to confluency in 96-well, flat-bottom plates and infected with HSV at a multiplicity of infection (MOI) of 10 or mock infected. In some assays, fibroblasts and CTL were pretreated with acyclovir or cycloheximide (CHX) for the times and concentrations indicated (acyclovir and CHX from Sigma-Aldrich, St. Louis, MO). After a 6-h infection of fibroblasts with HSV in DMEM with 2% FCS (medium), fibroblasts were washed with PBS. CTL were added in 100 l medium/well and incubated for 4 h at 37°C and 5% CO 2 . These CTL are restricted to MHC molecules not expressed on the inactivating fibroblasts, and thus the CTL do not recognize the fibroblasts (data not shown). HA-8 ϩ and HA-8 Ϫ LCL target cells (targets) were labeled with 100 -200 Ci of Na 2 51 CrO 4 (Amersham Pharamcia Biotech, Piscataway, NJ) for 2-4 h at 37°C, washed, and counted. If a three-cell sandwich chromium release assay was performed, 51 Cr-labeled targets in 100 l/well were added to the HSVinfected fibroblasts and CTL at various E:T ratios. Alternatively, HSVinactivated CTL were gently aspirated from HSV-infected fibroblasts. Visual inspection confirmed that fibroblasts were not removed during aspiration. Removed CTL were counted and added to new wells containing 51 Cr-labeled targets. CTL were incubated with 51 Cr-labeled targets for 5-6 h at 37°C. A total of 40 l of supernatant/well was removed, added to a LumaPlate, and counted in a scintillation counter (Packard, Meriden, CT). Spontaneous and maximal release were measured by adding medium or 5% IGEPAL (Sigma-Aldrich) to 51 Cr-labeled targets. The spontaneous release was always less than 20% of the maximal release. All wells were done in triplicate, and percentage of specific 51 Cr release (%SR) was calculated by the formula %SR ϭ ((mean experimental cpm Ϫ mean spontaneous cpm)/ (mean maximal cpm Ϫ mean spontaneous cpm)) ϫ 100. Percentage of inactivation ϭ ((%SR from control Ϫ %SR from inactivated)/(%SR from control)) ϫ 100, where the control group was CTL incubated on mockinfected fibroblasts and the inactivated group was CTL incubated on HSVinfected fibroblasts.
Redirected cell lysis
CTL were incubated with mock-or HSV-infected fibroblasts and removed, as described above. CTL were then incubated with a mAb raised against CD3 (clone OKT3; Ortho-McNeil, Redwood City, CA) at 1 g/ml for 15 min at 37°C. P815 cells overexpressing Fc␥R were kindly provided by V. Groh and T. Spies (Fred Hutchinson Cancer Research Center, Seattle, WA) (37) . P815 cells were labeled with 100 -200 Ci of Na 2 51 CrO 4 for 2 h at 37°C, washed, counted, and then added to OKT3-bound CTL at various E:T ratios for 6 h.
Flow cytometric analysis of granzyme A and cytokine production
CTL were incubated with mock-or HSV-infected fibroblasts and removed. Lytic granule content in CTL was determined by incubating CTL with LCL at an E:T ratio of 1:5 for 5 h. Cells were then stained with PerCP-conjugated anti-CD8 (clone SK1; BD PharMingen, San Diego, CA) and FITCconjugated anti-granzyme A Ab using the granzyme A reagent kit (clone CB9; BD PharMingen) and analyzed by flow cytometry.
To detect cytokine production, CTL were incubated with mock-or HSV-infected fibroblasts, as previously described, removed, and added to unlabeled LCL target cells at various E:T ratios for 6 h at 37°C. In some experiments, CTL were untreated, treated with 1 g/ml staphylococcal enterotoxin B (SEB), or treated with 100 ng/ml PMA plus 1 g/ml ionomycin for 6 h at 37°C (SEB, PMA, and ionomycin; Sigma-Aldrich). During the final 4 h of stimulation with BLCL or mitogens, 10 g/ml brefeldin A (BFA; Sigma-Aldrich) was added to prevent protein secretion and allow visualization of the retained cytokines. CTL were fixed, permeabilized, and stained with PerCP-conjugated anti-CD8 (clone SK1), FITC-conjugated anti-IFN-␥ (clone 25723.11), or FITC-conjugated anti-TNF-␣ (clone 6401.1111), following the manufacturer's suggested protocol (BD PharMingen), and analyzed by flow cytometry.
Flow cytometric analysis for T cell signaling and activationassociated cell surface Ags and ligands
CTL were incubated with mock-or HSV-infected fibroblasts, removed, and stained with FITC-, PE-, ECD-, or PC5-conjugated Abs. Abs from Beckman Coulter (Hialeh, FL) recognized: CD2 (clone T11), CD3 (UCHT1), CD5 (BL1a), CD7 (3A1E-12H7), CD8 (SFCi21Thy-2D3 and B9.11), CD28 (CD28.2), CD38 (T16), CD45 (J.33), and CD56 (N901). Abs from BD Biosciences (San Jose, CA) recognized: CD5 (L17F12), CD25 (2A3), CD56 (MY31), CD57 (HNK-1), and HLA-DR (L243). Fourcolor flow cytometry was performed on a Coulter XL instrument, and data were compensated and analyzed using software developed in the University of Washington Hematopathology Laboratory by B. Wood.
Levels of MHC class I-like molecules (MIC) were measured on mockand HSV-infected fibroblasts at 6 and 10 h postinfection with a mAb specific for MICA and MICB (clone 6D4 kindly provided by V. Groh) and analyzed with flow cytometry, as previously described (38) . A blocking Ab against CD94 (clone HP-3B1; Beckman Coulter) was added to control and inactivated CTL at 5 g per 1.5 ϫ 10 6 cells and incubated for 1 h before adding LCL targets at an E:T of 2 in a cell-mediated cytotoxicity assay (39) .
Flow cytometric analysis of apoptotic markers
CTL were incubated with mock-or HSV-infected fibroblasts, removed, and added to LCL. To distinguish BLCL from CTL, LCL were labeled with an integral membrane dye using the PKH26 Red Fluorescent Cell Linker Kit (Sigma-Aldrich). CTL and PKH26-labeled LCL were incubated at various E:T ratios for 5 h, and activated caspase 3 was measured using the active caspase 3 FITC mAb Apoptosis Kit I (clone C92-605; BD PharMingen). Cells were then paraformaldehyde fixed and analyzed by flow cytometry (40) .
Mitochondrial potential was assessed in untreated CTL, CTL treated with 1 M staurosporine (Sigma-Aldrich) for 4 h, CTL incubated with uninfected fibroblasts (control) for 4 h, and CTL incubated with HSVinfected fibroblasts (inactivated) for 4 h. CTL were then stained using MitoTracker Red CMXRos as per the manufacturer's instructions (Molecular Probes, Eugene, OR). Control and inactivated CTL were also stained with Ab against CD95/Fas (clone DX2; DAKO, Carpenteria, CA) and with the DNA-binding dye 7-amino-actinomycin D (Sigma-Aldrich) and analyzed by flow cytometry.
Quantitative real-time PCR using TaqMan chemistry
CTL were incubated with uninfected or HSV-infected fibroblasts for 4 h, removed by aspiration, and incubated for 5 h at 37°C. In the acyclovir group, fibroblasts were treated with 50 M acyclovir for 2 h before infecting with HSV for 6 h. Removed CTL were then incubated with CD8-conjugated Dynabeads (Dynal A.S., Oslo, Norway) for 30-min rocking at 4°C and washed, as directed by the manufacturer. DNA was purified from uninfected fibroblasts, HSV-infected fibroblasts, and CD8-enriched CTL using DNeasy tissue kits (Qiagen, Valencia, CA). DNA was quantified by spectrophotometry and used as template in TaqMan real-time PCR with primers and fluorogenic probes specific for the HSV glycoprotein B gene or the cellular ␤-globin gene. Reactions were done on an ABI 7700 sequencer (Applied Biosystems, Foster City, CA), and the sequences and concentrations of the primers and probes used were as previously described (41) .
Results

Effect of incubating CTL with fibroblasts infected with HSV-1 or HSV-2
To evaluate the possibility that HSV-infected cells might send an inactivating signal to CTL, a confluent fibroblast monolayer was mock or HSV infected for 6 h and washed. We then added a CD8 ϩ CTL clone that is restricted to MHC molecules not expressed on the fibroblasts (i.e., there was no killing of mock-or HSV-infected fibroblasts; data not shown). After incubating the HSV-infected fibroblasts and CTL for 4 h, 51 Cr-labeled target cells were added, and the three-cell sandwich was incubated for an additional 5 h. At an MOI of 10 (i.e., 10 PFU of HSV per fibroblast) and a wide range of E:T ratios, both HSV-1-infected and HSV-2-infected fibroblasts, but not uninfected fibroblasts, markedly inhibited the ability of CTL to kill targets (Fig. 1A) . We refer to this phenomenon as HSV-mediated inactivation, and it occurred at an MOI as low as 0.2 ( Fig. 1B) , suggesting a very robust negative signaling event between HSV-infected fibroblasts and CTL. To determine the kinetics of inactivation, the infection and CTL incubation times were varied independently. The ability of HSV-infected fibroblasts to cause inactivation occurred as soon as 2 h after infection and plateaued by 6 h with greater than 90% reduction of 51 Cr release (Fig. 1C) . At 6 h postinfection, inactivation was seen with as little as 1 h of CTL incubation with HSV-infected fibroblasts and was maximal by 3-4 h (Fig. 1D) .
When CTL were incubated for 4 h with supernatant from fibroblasts that had been infected with HSV for 6 h, there was no effect on CTL cytotoxicity as measured by a standard 51 Cr release assay (data not shown). Similarly, CTL were not inactivated when incubated with HSV-infected fibroblasts in a Transwell format that prevented contact between the two cell types (data not shown). These results suggest that CTL inactivation is not mediated by a soluble factor, but requires cell-to-cell contact.
To assess the durability of the inactivated phenotype, CTL were removed from HSV-infected fibroblasts by gentle aspiration. CTL removal also decreased the potential for CTL infection during subsequent steps and eliminated the possibility that HSV-infected fibroblasts might directly influence or infect target cells. A total of 80 -90% of CTL was typically removed without removing fibroblasts, as determined by microscopic inspection and counting (data not shown). Removed CTL were incubated alone before adding targets, and they remained inactivated for at least 12 h ( Fig. 2A) . Treatment with IL-2 maintained the lytic ability of CTL added to mock-infected fibroblasts for up to 48 h, but CTL added to HSVinfected fibroblasts did not recover killing function even when treated with IL-2 (Fig. 2B) .
In all subsequent experiments involving the HSV-mediated inactivation of CTL, fibroblasts were mock or HSV infected for 6 h at an MOI of 10, and CTL were incubated for 4 h with the mockor HSV-infected fibroblasts. CTL from mock-infected fibroblasts (control) and HSV-infected fibroblasts (inactivated) were then removed from the fibroblasts before adding to target cells. When inactivated CTL were mixed with control CTL at ratios as high as 1:1, there was no suppression of lytic ability in the control CTL (data not shown).
Although chromium release is a traditional method for determining the cytotoxic capacity of CTL, more biologically relevant methods have recently become available that examine apoptotic FIGURE 1. HSV-mediated inactivation of CTL intensifies as HSV infection of fibroblasts increases and CTL incubation with HSV-infected fibroblasts increases. A, Fibroblasts were mock infected or infected with HSV-1 or HSV-2 for 6 h at an MOI of 10. The alloreactive CD8 ϩ CTL clone SKH13 was then incubated for 4 h with HSV-infected fibroblasts. 51 Cr-labeled LCL target cells were added to wells containing HSV-infected fibroblasts and CTL at variable E:T ratios. B, Fibroblasts were infected for 6 h with HSV-2 at variable MOIs, and CTL were incubated for 4 h with HSV-infected fibroblasts. C, Fibroblasts were infected with HSV-2 for variable times at an MOI of 10, and CTL were incubated for 2 h with HSV-infected fibroblasts. D, Fibroblasts were infected for 6 h with HSV-2 at an MOI of 10, and CTL were incubated with HSV-infected fibroblasts for variable times. E:T ratios of 2 were used for B-D. All data points represent triplicate values from three-cell sandwich assays measuring specific 51 Cr release from LCL allogeneic target cells (HA-8 positive). 51 Cr release from autogeneic targets (HA-8 negative) Ͻ1% (data not shown). Control CTL ϭ CTL incubated on mock-infected fibroblasts. Inactivated CTL ϭ CTL incubated on HSV-infected fibroblasts. A representative of two independent experiments is shown. markers, such as activated caspase levels, in target cells (42) . We used flow cytometry to assess activated caspase 3 levels in targets incubated with control or inactivated CTL. Target cells were first labeled with the integral membrane dye PKH26 to distinguish them from CTL. In apoptotic cells, activated caspase 3 levels increase. In agreement with the chromium release data, targets incubated with inactivated CTL had substantially less activated caspase 3 relative to those incubated with control CTL (Fig. 3A) .
Caspase activation in target cells occurs primarily through the exocytosis of lytic granules from activated CTL. These granules contain perforin and granzymes A and B. The SKH13 CTL clone used this mechanism as well, because the addition of concanamycin, an agent that blocks granule exocytosis, prevented 51 Cr release from target cells (data not shown). We evaluated granzyme A levels in inactivated CTL after incubation with targets. Consistent with our previous assessment of cytotoxicity, there was markedly more granzyme A remaining in the inactivated CTL relative to control CTL (Fig. 3B) . Thus, HSV-inactivated CTL do not degranulate upon contact with target cells.
In addition to granule exocytosis, CTL control viral replication by synthesizing and secreting proinflammatory cytokines. To assess cytokine levels, CTL were treated with BFA, an agent that prevents secretion of proteins, during stimulation with target cells. Flow cytometric analysis revealed 90% less synthesis of IFN-␥ and TNF-␣ in inactivated CTL relative to control CTL (Fig. 4) . Therefore, CTL are inhibited in at least two mechanistically distinct effector pathways in our HSV-mediated inactivation model.
Cell surface markers involved in T cell costimulation, accessory signaling, and activation were measured on control and inactivated CTL. There was no detectable difference by flow cytometry for the following molecules: CD2, CD3, CD5, CD7, CD8, CD19, CD25, CD28, CD38, CD45, CD56, CD57, and HLA-DR (data not shown). An anti-CD94-blocking Ab added to CTL before incubating with HSV-infected fibroblasts did not alter inactivation, suggesting that the CD94-NKG2A molecules were also not involved. In addition, levels of the MIC, MICA and MICB, were similar on mock-and HSV-infected fibroblasts (data not shown).
HSV-mediated inactivation does not require infection of CTL
A possible explanation for inactivation of CTL in our model involves a negative signaling event between HSV-infected fibroblasts and uninfected CTL. This proposed mechanism is distinct from the inhibition of CTL function that occurs when CTL are infected with HSV. To determine whether viral replication was necessary in HSV-infected fibroblasts and to decrease the possibility of cell-to-cell spread of virus to CTL, fibroblasts were treated with acyclovir before infection. In HSV-infected cells, viral gene expression is divided temporally into three classes: immediate early (␣), early (␤), and late (␥ 1 and ␥ 2 ) genes. Acyclovir inhibits spread of virus from one infected cell to another by inhibiting viral DNA synthesis. As a result of inhibiting replication of viral DNA, ␥ 2 gene expression is also inhibited. HSV-infected fibroblasts retained the capacity to inactivate CTL in the presence of 50 and 500 M acyclovir (Fig. 5) . As a follow-up to this finding, a carry-over 4. HSV-inactivated CTL synthesize decreased cytokine levels when stimulated with target cells. SKH13 CTL were inactivated, as previously described, with HSV-2-infected fibroblasts and removed before adding to target cells for 6 h at an E:T ratio of 0.2. BFA was added for the last 4 h of incubation between CTL and targets at a concentration of 10 g/ml to prevent protein secretion. Cells were then stained with Ab against CD8, IFN-␥, and TNF-␣ and analyzed by flow cytometry. A representative of three independent experiments is shown.
FIGURE 5.
Acyclovir has a minimal effect on HSV-mediated inactivation of CTL. Fibroblasts were untreated or treated with 50 or 500 M acyclovir for 2 h before a 6-h infection with HSV-2. CTL were added to HSV-infected or mock-infected fibroblasts for 4 h and then removed by aspiration. Control and inactivated CTL were added to target cells at an E:T ratio of 3 for 6 h. A representative of three independent experiments using both the SKH13 and KSN CTL clones is shown. experiment was conducted. CTL were inactivated on acyclovirtreated, HSV-infected fibroblasts and removed. Inactivated CTL were then incubated with uninfected fibroblasts for 5 days. After 5 days, there were no cytopathological effects (i.e., microscopic changes in cell morphology that occur after infection with virus) on the fibroblasts incubated with inactivated CTL (data not shown). These results suggest that viral replication is not necessary for CTL inactivation by HSV-infected cells and that ␥ 2 viral genes are not required for inactivation in our model.
Although acyclovir treatment substantially decreases the production of virus from infected cells, it does not rule out the possibility that HSV-inactivated CTL become infected in our model. The most sensitive technique available to detect the presence of HSV is real-time, quantitative PCR. Primers and probes against a viral gene (gB) and a cellular gene (␤-globin) were used to determine the number of HSV copies per cell in HSV-infected fibroblasts and in inactivated CTL. Fibroblasts were untreated or treated with 50 M acyclovir before infection. CTL were then inactivated as before, removed, and enriched using CD8-coupled magnetic beads to decrease possible contamination with HSV-infected fibroblasts. Although fibroblasts treated with acyclovir and infected with HSV were capable of inactivating CTL, we detected only 1 copy of HSV per 6 CTL in this group, a value that approached the mock-infected background level of 1 copy of HSV per 29 fibroblasts (Table I ). In the group without acyclovir treatment, HSVinfected fibroblasts contained 4344 copies of HSV per cell. CTL incubated on HSV-infected fibroblasts contained 6.5 copies of HSV per cell ( Table I ), suggesting that cell-to-cell spread of HSV from infected fibroblasts to CTL was a relatively rare event even in the absence of acyclovir. In summary, it is clear that HSVmediated inactivation of CTL can occur in the absence of CTL infection in our model.
Analysis of apoptosis in HSV-inactivated CTL
The same numbers of CTL were recovered by aspiration from HSV-infected fibroblasts as from uninfected fibroblasts, and trypan blue staining revealed no evidence of preferential loss of viability in CTL after contact with HSV-infected fibroblasts (data not shown). However, this is a crude indicator of cell health. Therefore, activated caspase 3 levels in CTL were measured by flow cytometry to determine whether apoptosis played a role in our inactivation model. The percentage of control and inactivated CTL staining positive for activated caspase 3 was virtually equal (Fig.  6A) . Another indicator of programmed cell death is the loss of mitochondrial membrane potential. CMXRos is a charge-sensitive fluorochrome that binds to the inner mitochondrial membrane and decreases in fluorescence as membrane potential is lost. In our model, HSV-inactivated CTL had a mitochondrial potential very similar to control CTL, whereas CTL treated with staurosporine, an agent that induces apoptosis through the mitochondrial pathway, showed a significant decrease in the CMXRos signal (Fig.  6B ). In addition, flow cytometry revealed no detectable difference in CD95 (Fas) levels or in binding of 7-amino actinomycin D to inactivated and control CTL (data not shown). Taken together, these results suggest no evidence of increased programmed cell death in CTL inactivated by HSV-infected cells.
Stimulating HSV-inactivated CTL through the TCR or with a phorbol ester plus ionomycin
Our results demonstrated that HSV-inactivated CTL were not apoptotic nor were they infected with HSV. Furthermore, the inactivated phenotype was sustainable and not altered by IL-2 treatment (Fig. 2) . Incubation of inactivated CTL with SEB, a superantigen that functions through TCR complex triggering, led to an increase in IFN-␥ synthesis in control, but not inactivated CTL (Fig. 7A) . Similarly, control, but not inactivated CTL were capable of lytic granule release via redirected lysis using anti-CD3 Ab-labeled CTL and 51 Cr-labeled P815 cells that express abundant Fc␥R (Fig. 7B) . In contrast, treatment of inactivated CTL with PMA plus ionomycin, a non-TCR method of stimulation, resulted in the production of IFN-␥ levels comparable with control CTL (Fig. 7C) . Taken together, these findings suggest that although HSV-inactivated CTL cannot be stimulated through the TCR, they a TaqMan chemistry used previously published primers and probes against HSV glycoprotein B (gB) gene and the cellular ␤-globin gene (41) .
b Fibroblasts, untreated or treated with 50 M acyclovir, were infected for 6 h with HSV-2 or mock-infected. CTL were added for 4 h and removed, then incubated for 5 h alone. CTL were enriched using CD8-coupled magnetic beads.
c DNA was extracted from cells and used as template. Number of HSV copies was determined by C t values for gB at a given template dilution, and number of cells was determined by C t values for ␤-globin at the same template dilution.
FIGURE 6.
Inactivation of CTL is not due to apoptosis. A, KSN CTL were inactivated as before and removed from HSV-2-infected fibroblasts before adding to PKH26-labeled target cells at an E:T ratio of 1 for 5 h. Cells were stained with Ab against activated caspase 3 and analyzed by flow cytometry. CTL were selected by gating for PKH26-negative events. B, In the top two panels, SKH13 CTL were not added to fibroblasts. They were incubated in the presence or absence of 1 M staurosporine (STS) for 4 h. In the bottom two panels, SKH13 CTL were inactivated on HSV-2-infected fibroblasts and removed, as previously described. All CTL were subsequently stained with CMXRos and analyzed by flow cytometry. A representative of two independent experiments is shown for experiments with each clone.
are viable and retain the capacity to functionally respond to other signaling pathways.
Effect of UV irradiation and CHX on HSV-mediated inactivation
To determine whether the input virion was sufficient to inactivate CTL, HSV was UV irradiated before infecting fibroblasts. At 0.1 J of UV irradiation, virus was still capable of cell entry (data not shown), but inactivation of CTL was virtually abolished (Fig. 8A) . This indicates that de novo viral protein synthesis is required to inactivate CTL. To confirm these findings, CHX was used to independently inhibit translation in fibroblasts, CTL, and target cells. Inactivation of CTL by HSV-infected fibroblasts was done, as previously described, except that each cell type was first treated with 10 g/ml CHX. Although there was no effect on HSV-mediated inactivation when CTL or targets were exposed to CHX, treating the fibroblasts with CHX before infection abolished HSV-mediated inactivation (Fig. 8B) . Therefore, protein synthesis is necessary in HSV-infected fibroblasts, but not in CTL in order for inactivation to occur.
Analysis of HSV deletion-rescue pairs in HSV-mediated inactivation of CTL
To identify viral genes that HSV-infected cells require to mediate inactivation, we used deletion-rescue pairs derived from the HSV-1 F parent strain. Fibroblasts infected with viruses containing deletions in ␣4 or U L 54 were incapable of inactivating CTL, while deletion of U s 12 did not alter HSV-mediated inactivation (Fig. 9) . Deletion of U S 5 did not prevent inactivation. However, deletion of U S 3 significantly decreased the ability of HSV-infected fibroblasts to inactivate CTL (Fig. 9 , p Ͻ 0.005 using paired Student's twotailed t test).
Discussion
Our results demonstrate that HSV-infected cells engage a powerful signaling pathway in CD8 ϩ CTL and dramatically inhibit their FIGURE 7. HSV-inactivated CTL cannot respond to TCR complex stimulation, but can respond to PMA plus ionomycin. SKH13 CTL were inactivated and removed as before. A, Inactivated and control CTL were untreated or treated with SEB at 1 g/ml for 6 h. The final 4 h was in the presence of BFA at 10 g/ml to prevent protein secretion. Cells were stained with Ab against CD8 and IFN-␥ and analyzed by flow cytometry. B, Redirected lysis assay. CTL were incubated with Ab against CD3 at 1 g/ml for 15 min before adding to 51 Cr-labeled Fc␥R ϩ P815 target cells at various E:T ratios for 5 h. C, CTL were treated with PMA at 100 ng/ml plus ionomycin at 1 g/ml for 6 h (BFA at 10 g/ml was added for the final 4 h). CTL were then stained with Ab against IFN-␥ and analyzed by flow cytometry. A representative of three independent experiments is shown.
FIGURE 8.
Fibroblasts infected with UV-irradiated HSV and fibroblasts treated with CHX before HSV infection cannot inactivate CTL. SKH13 CTL were inactivated and removed as before and added to target cells at an E:T ratio of 3. A, HSV-2 was UV irradiated on ice with 0.1 J in a Stratalinker. The control group consisted of CTL incubated with mockinfected fibroblasts. HSV and UV-HSV groups consisted of CTL incubated with fibroblasts infected with HSV or UV-irradiated HSV, each at an MOI of 10. B, The cell types indicated were treated with CHX at 10 g/ml, and CHX was maintained throughout the assay. Fibroblasts were treated for 10 h before infection, CTL were treated for 5 h before incubating with fibroblasts, and targets were treated at the time of addition to CTL. The percentage of inactivation represents a decrease in specific 51 Cr release. A representative of two independent experiments is shown.
FIGURE 9.
The HSV immediate early genes ␣4 and U L 54 and the late gene U S 3 are required for the inactivation of CTL. CTL were inactivated and removed from the indicated HSV-infected fibroblasts, as previously described, and then added to labeled target cells at an E:T ratio of 3 for 5 h in a standard 51 Cr release assay. Each deletion-rescue pair was derived from a HSV-1 F parent strain and was deficient for the gene indicated. A representative of three independent experiments using both SKH13 and KSN CTL is shown. effector functions. CTL inactivated by HSV-infected cells lose their ability to release cytolytic granules and synthesize cytokines when triggered through the TCR. (42, 43) . In addition, our findings indicate that the inactivating receptor is expressed constitutively on CTL, because inhibition of new protein synthesis in CTL does not prevent inactivation. Finally, the inactivating receptor inhibits effector function without affecting cell viability, as inactivated CTL are not apoptotic and can respond to PMA. PMA is thought to function by activating the protein kinase C pathway (44) , which suggests that the inactivating signal inhibits TCR signaling proximal to protein kinase C.
To rule out known mechanisms of CTL inhibition as an explanation for inactivation in our model, we examined several possibilities. Whereas IL-2 treatment restores CTL function in traditional anergy models (45), IL-2 does not restore function in our inactivation model. The inactivated phenotype is not transferable from inactivated CTL to control CTL, a feature characteristic of the regulatory T cell phenotype (46) . Although inhibition of cytolytic function has been reported in HIV-specific CTL (47), IFN-␥ secretion was unaltered. This is different from CTL inactivated by HSV-infected cells, in which the lytic granule and cytokine pathways are both inhibited. Another possible explanation for inactivation could be a loss of TCR signal strength due to decreased levels of CD3 or CD8. However, these molecules were unaltered on inactivated CTL relative to control CTL. Alternatively, inactivation could be due to down-regulation of a CTL receptor involved in costimulation, such as CD28. CD28 is necessary for CTL cytotoxicity, cytokine secretion, and clonal expansion (48 -50) , and TCR ligation in the absence of costimulation can lead to CTL anergy and apoptosis (51) . We found no difference between control and inactivated CTL in CD28 levels. In summary, the inactivating signal between HSV-infected cells and CTL produces an impaired phenotype distinct from several known CTL silencing mechanisms, and it is possible that the inactivated phenotype we describe represents a novel form of CTL quiescence.
There is an increasing body of literature describing families of related receptors on CTL that have opposing functions and facilitate the equilibrium between initiation and termination of a CTL response. These reports suggest that a complex equilibrium exists between CTL and cells they encounter at various points in the immune response. NK cell receptors found on many CTL, such as CD94-NKG2, can initiate both positive and negative regulatory pathways by binding various MHC class I and MIC on APC and target cells (52, 53) . There is evidence in the literature for altered expression of CTL regulatory ligands and receptors in virus-infected cells. For example, elevated levels of MICA and MICB are reported in CMV-infected cells (54) , and the inhibitory CD94-NKG2A receptor is up-regulated in polyoma virus-induced oncogenesis (55) . However, we detected no difference in MICA or MICB levels between mock-infected and HSV-infected fibroblasts, and CD94-blocking Abs did not prevent inactivation of CTL. Therefore, our model also appears to be distinct from these known mechanisms of CTL inhibition.
In addition to examining known mechanisms of CTL inhibition, we wanted to determine the viral requirements for inactivation. Cells infected with UV-inactivated HSV were not capable of inactivating CTL, suggesting that HSV-infected cells require new viral protein synthesis to transmit the inactivating signal to CTL. The use of deletion-rescue pairs revealed some of the viral genes required for HSV-infected fibroblasts to inactivate CTL. The ␣ trans-activating genes ␣4 and U L 54 are required for the expression of numerous ␤ and ␥ genes. Not surprisingly, deletion of either gene abolished HSV-mediated inactivation, while deletion of U S 12, a non-trans-activating ␣ gene, had no effect. From these results, it was clear that HSV-infected fibroblasts required one or more downstream viral genes (␤ or ␥ 1 ) to transmit the inactivating signal to CTL. Because our lab has been studying the roles that U S 3 and U S 5 play in protecting virally infected cells from undergoing apoptosis, HSV deletions for these genes were available and tested. As predicted from experiments using acyclovir in which ␥ gene expression should have been minimal, but inactivation still occurred, deletion of the ␥ gene U S 5 did not affect inactivation. However, deletion of the ␤ gene U S 3 diminished the inactivation signal to a level comparable to the ␣4 or U L 54 deletions.
There are several known mechanisms by which U S 3 might be influencing the ability of HSV-infected cells to inactivate CTL. U S 3 reportedly phosphorylates both viral and cellular proteins, affecting their expression and function. Known viral substrates for U S 3 include the immediate early regulatory proteins ICP22 and U S 1.5, as well as U L 34, and U L 3 (56 -58). U S 3 has also been shown to inhibit apoptosis in HSV-infected cells by modifying cellular proteins (22, 59) . For example, U S 3 can posttranslationally modify Bad, a proapoptotic member of the Bcl-2 family, and prevent it from activating programmed cell death (60) .
The significance of U S 3 in our model of CTL inactivation is illustrated by an in vivo model of murine HSV-2 genital herpes (61) . In this model, there was more rapid viral clearance in mice infected with a U S 3-deficient mutant relative to a U S 2 mutant or wild-type virus. In addition, the U S 3-deficient mutant produced an immune response with increased number of CD8 ϩ T cells and increased levels of secreted IFN-␥. This finding was largely attributed to the known antiapoptotic function of U S 3. However, our findings shed new light on this model. It is possible that the enhanced CTL response in the U S 3-deficient mutant was secondary to a loss of inactivation of CTL, suggesting that the inactivating signal from HSV-infected cells might be an important feature in the successful ability of HSV to infect, replicate, and persist in vivo.
We report that U S 3 expression in HSV-infected cells is necessary to transmit the inactivating signal. We have not established that U S 3 expression is sufficient to inactivate CTL. The U S 3 amino acid sequence does not have a predicted transmembrane domain or a signal sequence or GPI linkage. Therefore, U S 3 is unlikely to be found on the cell surface and probably does not act directly as the inactivating ligand. A more likely role for U S 3 is to modify, possibly phosphorylate, a viral or cellular protein functioning as the inactivating ligand. Identifying the ligand on U S 3-expressing, HSV-infected cells responsible for inactivating CTL could provide a means of specifically manipulating CTL function. This, in turn, could lead to the ability to stimulate dysfunctional CTL that exist in persistent viral infections and tumor states, or alternatively to promote inactivation in graft-vs-host disease, transplant rejection, and autoimmune states.
